What is HC Wainwright's Estimate for Alkermes Q1 Earnings?

Alkermes plc (NASDAQ:ALKS - Free Report) - Analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Alkermes in a note issued to investors on Thursday, February 13th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $0.22 per share for the quarter, down from their prior estimate of $0.27. HC Wainwright currently has a "Neutral" rating and a $46.00 price target on the stock. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. HC Wainwright also issued estimates for Alkermes' Q2 2025 earnings at $0.31 EPS and Q4 2025 earnings at $0.39 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Other analysts have also issued reports about the stock. JPMorgan Chase & Co. cut their target price on shares of Alkermes from $32.00 to $26.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. Mizuho raised their price objective on shares of Alkermes from $35.00 to $40.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. The Goldman Sachs Group increased their target price on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a report on Friday, February 14th. Stifel Nicolaus upgraded Alkermes from a "hold" rating to a "buy" rating and raised their price target for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. Finally, Cantor Fitzgerald lowered their price objective on Alkermes from $48.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Alkermes presently has an average rating of "Moderate Buy" and an average price target of $37.25.

Alkermes Trading Down 0.9 %

NASDAQ:ALKS traded down $0.34 during midday trading on Monday, reaching $35.50. The company had a trading volume of 1,276,584 shares, compared to its average volume of 1,731,003. The stock's fifty day simple moving average is $30.69 and its 200-day simple moving average is $28.98. Alkermes has a 12-month low of $22.90 and a 12-month high of $36.45. The firm has a market capitalization of $5.77 billion, a price-to-earnings ratio of 16.36, a PEG ratio of 2.24 and a beta of 0.49.

Insiders Place Their Bets

In related news, Director Cato T. Laurencin sold 2,691 shares of the business's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now directly owns 23,013 shares of the company's stock, valued at $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Craig C. Hopkinson sold 9,221 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $31.50, for a total value of $290,461.50. Following the transaction, the executive vice president now directly owns 59,730 shares in the company, valued at approximately $1,881,495. This represents a 13.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 323,608 shares of company stock valued at $10,854,725 in the last ninety days. Corporate insiders own 4.89% of the company's stock.

Institutional Investors Weigh In On Alkermes

A number of institutional investors have recently modified their holdings of ALKS. RTW Investments LP grew its holdings in shares of Alkermes by 13.6% during the fourth quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock valued at $217,363,000 after purchasing an additional 903,802 shares during the last quarter. Renaissance Technologies LLC boosted its position in Alkermes by 1.1% during the 4th quarter. Renaissance Technologies LLC now owns 5,478,728 shares of the company's stock valued at $157,568,000 after purchasing an additional 57,697 shares during the period. American Century Companies Inc. grew its stake in Alkermes by 6.5% during the 4th quarter. American Century Companies Inc. now owns 3,450,707 shares of the company's stock worth $99,242,000 after buying an additional 209,740 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Alkermes by 4.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,019,508 shares of the company's stock worth $86,842,000 after buying an additional 128,701 shares during the period. Finally, Avoro Capital Advisors LLC bought a new stake in Alkermes in the fourth quarter valued at $70,462,000. Institutional investors own 95.21% of the company's stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.